Earnings Per Share
EPS (Diluted)
Royalty Pharma EPS (Diluted) increased by 34.0% to $0.67 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.8%, from $0.55 to $0.67. Over 3 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 6.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher values indicate stronger profitability even when accounting for potential share dilution.
Detailed definition
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Peer comparison
Used by all public companies to provide a realistic view of earnings per share for investors.
Metric ID:
eps_dilutedHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.08 | $0.24 | $0.00 | $0.12 | $0.70 | $0.32 | $0.76 | $0.50 | $0.16 | $1.10 | $0.01 | $0.23 | $1.21 | $0.47 | $0.55 | $0.07 | $0.67 | $0.50 | $0.67 |
| QoQ Change | — | -77.8% | -100.0% | — | +483.3% | -54.3% | +137.5% | -34.2% | -68.0% | +587.5% | -99.1% | >999% | +426.1% | -61.2% | +17.0% | -87.3% | +857.1% | -25.4% | +34.0% |
| YoY Change | — | — | — | — | -35.2% | +33.3% | +533.3% | -28.6% | -50.0% | — | -98.7% | -54.0% | +656.3% | -57.3% | >999% | -69.6% | -44.6% | +6.4% | +21.8% |
Range$0.00 – $1.21
CAGR-10.1%
Avg YoY Growth+443.8%
Median YoY Growth-31.9%
EPS (Diluted) at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's eps (diluted)?
- Royalty Pharma (RPRX) reported eps (diluted) of $0.67 in Q1 2026.
- How has Royalty Pharma's eps (diluted) changed year-over-year?
- Royalty Pharma's eps (diluted) increased by 21.8% year-over-year, from $0.55 to $0.67.
- What is the long-term trend for Royalty Pharma's eps (diluted)?
- Over 3 years (2021 to 2025), Royalty Pharma's eps (diluted) has grown at a 6.1% compound annual growth rate (CAGR), from $1.50 to $1.79.
- What does eps (diluted) mean?
- Earnings per share calculated as if all potential shares were issued.